ClinicalTrials.gg
CompletedNCT04245215REScUEUpdated Jul 1, 2026Results posted

Loss of RESponse to Ustekinumab Treated by Dose Escalation

A Phase 3 interventional study of Ustekinumab in Crohn Disease, sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing ustekinumab in Crohn Disease — 3 open to participants now, 5 under way, 2 of them phase 3. Ustekinumab · Crohn Disease.

Enrollment
13th of 21
108 · median 131
Started
2020
with 1 other
Phase 3
8 of 21
none open now
Registered
12th of 21
by date
Lead sponsor
2 of 21
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

Among the 21 studies testing ustekinumab in Crohn Disease, this one is the 13th largest by enrollment, is one of 2 that started in 2020, is one of 8 in phase 3, and was the 12th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

3 of the 21 studies testing ustekinumab in Crohn Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ustekinumab

Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing ustekinumab in Crohn Disease, or all of them as a file.
02

Study summary

The aim of the study is to investigate the effect of re-induction with ustekinumab ≈6mg/kg IV followed by two different maintenance dosing regimens 90 mg subcutaneous every 8 weeks (Q8W) vs 90 mg subcutaneous every 4 weeks(Q4W) on clinical, biological and pharmacological outcomes in patients with Crohn's disease who show a secondary loss of response over time

Read the detailed description

The study is a prospective double blind interventional study in patients with Crohn Disease treated with ustekinumab that show an objective secondary loss of response to ustekinumab after induction treatment (>Week 16). Patients can be screened during a four week period. The screening includes a clinical, biochemical and endoscopic assessment. Patients will be randomized 8 weeks after the last subcutaneous injection with ustekinumab. All patient will receive an intravenous re-induction with ustekinumab ≈6mg/kg at baseline (8 weeks after last subcutaneous administration). After the intravenous re-induction, the patients receive either ustekinumab 90 mg subcutaneous Q4W or Q8W (altered with q8w placebo to mimic Q4W injections) till week 48. Clinical and biochemical evaluation will be planned every 8 weeks until week 36 with a final evaluation at week48. Primary endpoint will be assessed at week 48. Final assessment at week 48 will include clinical, biochemical and endoscopic evaluation.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • dose escalation
  • ustekinumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years
  2. Diagnosis of Crohn's disease by endoscopic and/or radiologic examination.
  3. Patient currently treated with ustekinumab, independent of previous biological exposure.
  4. Patients treated with maintenance dose of ustekinumab subcutaneous 90 mg every 8 weeks
  5. Documented primary response at any time point during induction (up to week 20) defined as a clinical response (physician discretion) AND confirmed by either any of the following:

1. A documented decrease in biomarkers based on a value during induction period compared to a value prior to ustekinumab induction (max. 3 months prior to start of ustekinumab induction)

a. A decrease in CRP OR b. A decrease in FCP 2. A documented endoscopic improvement (evaluation during the induction period compared to an evaluation prior to ustekinumab induction (max. 6 months prior to start of ustekinumab induction) 6. Documented loss of response after induction (at any timepoint after week 16) assessed by the physician as moderate to severe active Crohn's disease. The increase in symptoms reported by the patient is defined as Patient Reported Outcome-2 (Abdominal Pain > 1 AND Stool Frequency > 3) AND confirmed by either any of the following* :

  1. Documentation of endoscopic lesions in at least one segment of the ileum or colon as assessed by ileocolonoscopy AND a documented increase in biomarkers based on an increased value compared to the lowest value obtained during induction or after week 16 ustekinumab induction

    1. An increase in CRP and > 5 mg/L OR
    2. An increase in FCP and > 250µg/mg
  2. A documented relapse on endoscopy : Presence of mucosal ulcers in at least one segment of the ileum or colon and a SES-CD ≥ 6 (for patients with isolated ileitis ≥ 4), as assessed by ileocolonoscopy.

7. Adequate in female of reproductive age (oral contraception, intra uterine device, sterilisation or barrier method) 8. Have the capacity to understand and sign an form. 9. Be able to adhere to the study visit schedule and other protocol requirements.

10. All Crohn's Disease treatments stable for at least 2 weeks prior to baseline.

* the criterium used to proof loss of response does not have to be identical to the one used to proof primary response : e.g. one can use an increase in biomarkers to proof primary response and a relapse on endoscopy to proof loss of response

Exclusion criteria

Exclusion Criteria:

  1. Ongoing treatment with

    1. other concomitant biological (vedolizumab, anti-TNF)
    2. >20 mg prednisolone or equivalent at baseline (budesonide >6 mg, > 5mg beclomethasone dipropionate at baseline)
    3. Q4w ustekinumab (ustekinumab treatment every four weeks)
  2. Women that are pregnant, nursing, or planning pregnancy
  3. Have screening laboratory test results within the following parameters:

    1. \< 8.5 g/dL
    2. \< 100,000 /mm3
    3. Serum creatinine ≥ 1.7 mg/dL
    4. and alanine aminotransferase > 3 times the
    5. Direct (conjugated) ≥ 3.0 mg/dL.
  4. Have current signs or symptoms of infection confirmed by positive stool or blood testing (including gastrointestinal pathogens, tuberculosis, , , ).
  5. Patients with a positive stool sample for gastrointestinal pathogen including Clostridium difficile.
  6. Evidence of current or previous disease, medical condition other than Crohn's Disease, finding of the medical examination, or laboratory value at the screening visit outside the reference range that is of clinical relevance, that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.
  7. Patients with an ileostomy
  8. Patients that received an intravenous re-induction with ustekinumab within the 6 months prior to baseline.
  9. Patients with an impassable stenosis even after attempt of endoscopic balloon dilation.
  10. Patients with an abscess
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Placebo comparator
    1. Subcutaneous ustekinumab every 8 weeks

    re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections

    Drug: Ustekinumab

  • Active comparator
    2. Subcutaneous ustekinumab every 4 weeks

    re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks

    Drug: Ustekinumab

Interventions

  • re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2

    Also known as: dose escalation only in arm 2

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With Steroid Free Clinical Remission and Fecal Calprotectin<250µg/g at Week 48

    Proportion of patients with steroid free clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) and fecal calprotectin\<250µg/g at week 48. \[stool frequency (ST): average number of liquid stools for 1 week abdominal pain (AP): average scoring for abdominal pain for 1 week (0=none; 1=mild, 2=moderate; 3= severe)\]

    Time frame: week 48

Secondary outcomes

  1. Proportion of Patients With Complete Endoscopic Remission at Week 48

    Proportion of patients with complete endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD )\<3) at week 48

    Time frame: week 48

  2. Proportion of Patients With Endoscopic Remission at Week 48

    Proportion of patients with endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD) \<5) at week 48

    Time frame: week 48

  3. Proportion of Patients With Endoscopic Response at Week 48

    Proportion of patients with endoscopic response (≥50% decrease in simple endoscopic score for Crohn's disease (SES-CD)) at week 48

    Time frame: week 48

  4. Proportion of Patients With Clinical Remission at Week 8

    Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 8

    Time frame: week 8

  5. Proportion of Patients With Clinical Remission at Week 48

    Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 48

    Time frame: week 48

  6. Proportion of Patients With Biomarker Remission at Week 48

    Proportion of patients with biomarker remission (C-reactive protein \<5 mg/L and fecal calprotectin \<250 µg/g) at week 48

    Time frame: week 48

  7. Proportion of Patients With Serious Adverse Events at Week 48

    Proportion of patients with serious adverse events at week 48

    Time frame: Week 48

07

Results

Posted Apr 13, 2026

Participant flow

Between February 2020 and October 2023 a total of 132 patients were screened and 108 patients were randomized. First Patient In (FPI) was on 11Mar2020. Last Patient In (LPI) was on 17Oct2023. Last Patient Out (LPO) was on 25Sep2024.

Participant flow — Overall Study
MilestoneUstekinumab q4wUstekinumab q8w
Started5454
Completed3735
Not completed1719

Outcome measures

PrimaryProportion of Patients With Steroid Free Clinical Remission and Fecal Calprotectin<250µg/g at Week 48

Proportion of patients with steroid free clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) and fecal calprotectin\<250µg/g at week 48. \[stool frequency (ST): average number of liquid stools for 1 week abdominal pain (AP): average scoring for abdominal pain for 1 week (0=none; 1=mild, 2=moderate; 3= severe)\]

Time frame:
week 48
Reported as:
Count of participants · Participants
Proportion of Patients With Steroid Free Clinical Remission and Fecal Calprotectin<250µg/g at Week 48
ParticipantsUstekinumab q4wUstekinumab q8w
Proportion of Patients With Steroid Free Clinical Remission and Fecal Calprotectin<250µg/g at Week 48810
Statistical analysis
  • Ustekinumab q4w vs Ustekinumab q8w · Regression, Logistic · p = 0.5 · Risk difference (rd): 0.0502 · 95% CI -0.09487 to 0.1953
SecondaryProportion of Patients With Complete Endoscopic Remission at Week 48

Proportion of patients with complete endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD )\<3) at week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Proportion of Patients With Complete Endoscopic Remission at Week 48
ParticipantsUstekinumab q4wUstekinumab q8w
Proportion of Patients With Complete Endoscopic Remission at Week 4843
Statistical analysis
  • Ustekinumab q4w vs Ustekinumab q8w · Cochran-Mantel-Haenszel · p = 0.8 · Odds ratio (or): 0.787 · 95% CI 0.164 to 3.792
SecondaryProportion of Patients With Endoscopic Remission at Week 48

Proportion of patients with endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD) \<5) at week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Proportion of Patients With Endoscopic Remission at Week 48
ParticipantsUstekinumab q4wUstekinumab q8w
Proportion of Patients With Endoscopic Remission at Week 48158
Statistical analysis
  • Ustekinumab q4w vs Ustekinumab q8w · Cochran-Mantel-Haenszel · p = 0.1 · Odds ratio (or): 0.467 · 95% CI 0.178 to 1.223
SecondaryProportion of Patients With Endoscopic Response at Week 48

Proportion of patients with endoscopic response (≥50% decrease in simple endoscopic score for Crohn's disease (SES-CD)) at week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Proportion of Patients With Endoscopic Response at Week 48
ParticipantsUstekinumab q4wUstekinumab q8w
Proportion of Patients With Endoscopic Response at Week 48128
Statistical analysis
  • Ustekinumab q4w vs Ustekinumab q8w · Cochran-Mantel-Haenszel · p = 0.7 · Odds ratio (or): 0.837 · 95% CI 0.320 to 2.187
SecondaryProportion of Patients With Clinical Remission at Week 8

Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 8

Time frame:
week 8
Reported as:
Count of participants · Participants
Proportion of Patients With Clinical Remission at Week 8
ParticipantsUstekinumab q4wUstekinumab q8w
Proportion of Patients With Clinical Remission at Week 81921
Statistical analysis
  • Ustekinumab q4w vs Ustekinumab q8w · Cochran-Mantel-Haenszel · p = 0.7 · Odds ratio (or): 1.143 · 95% CI 0.526 to 2.484
SecondaryProportion of Patients With Clinical Remission at Week 48

Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Proportion of Patients With Clinical Remission at Week 48
ParticipantsUstekinumab q4wUstekinumab q8w
Proportion of Patients With Clinical Remission at Week 481618
Statistical analysis
  • Ustekinumab q4w vs Ustekinumab q8w · Cochran-Mantel-Haenszel · p = 0.6 · Odds ratio (or): 1.278 · 95% CI 0.562 to 2.904
SecondaryProportion of Patients With Biomarker Remission at Week 48

Proportion of patients with biomarker remission (C-reactive protein \<5 mg/L and fecal calprotectin \<250 µg/g) at week 48

Time frame:
week 48
Reported as:
Count of participants · Participants
Proportion of Patients With Biomarker Remission at Week 48
ParticipantsUstekinumab q4wUstekinumab q8w
Proportion of Patients With Biomarker Remission at Week 481813
Statistical analysis
  • Ustekinumab q4w vs Ustekinumab q8w · Cochran-Mantel-Haenszel · p = 0.3 · Odds ratio (or): 0.630 · 95% CI 0.268 to 1.483
SecondaryProportion of Patients With Serious Adverse Events at Week 48

Proportion of patients with serious adverse events at week 48

Time frame:
Week 48
Reported as:
Count of participants · Participants
Proportion of Patients With Serious Adverse Events at Week 48
ParticipantsUstekinumab q4wUstekinumab q8w
Proportion of Patients With Serious Adverse Events at Week 4897

Adverse events

Collected over From signature of informed consent form up to week 48 in the study. For SAE's up to 60 days after the last study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ustekinumab q4w0/54 (0%)9/54 (16.7%)44/54 (81.5%)
Ustekinumab q8w0/54 (0%)7/54 (13%)46/54 (85.2%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventUstekinumab q4wUstekinumab q8w
(sub)obstructionGastrointestinal disorders3/541/54
Abdominal painGastrointestinal disorders0/542/54
Flare of Crohn's DiseaseGastrointestinal disorders2/540/54
abdominal pain after right hemicolectomyInjury, poisoning and procedural complications0/541/54
Cardiac AblationSurgical and medical procedures1/540/54
Laparoscopic right hemicolectomySurgical and medical procedures0/541/54
Extensive colitisGastrointestinal disorders1/540/54
gastro-enteritisGastrointestinal disorders0/541/54
Small bowel ileusGastrointestinal disorders0/541/54
Bowel obstruction terminal ileitisGastrointestinal disorders1/540/54
Most frequent other events
Showing 10 of 11
Most frequent other events
EventUstekinumab q4wUstekinumab q8w
respiratory infectionInfections and infestations21/5425/54
musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders18/5422/54
lab abnormalities/deficienciesMetabolism and nutrition disorders10/5415/54
Abdominal painGastrointestinal disorders10/5413/54
Skin abnormalitiesSkin and subcutaneous tissue disorders6/549/54
fatigueGeneral disorders8/545/54
fluInfections and infestations7/548/54
headacheNervous system disorders5/547/54
Worsening of Crohn's DiseaseGastrointestinal disorders6/544/54
psychiatric symptomsPsychiatric disorders5/543/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ustekinumab q4wUstekinumab q8wTotal
Median41 (32 to 57)40 (32 to 53)41 (32 to 54)
Sex: Female, Male
Sex: Female, Male(Participants)Ustekinumab q4wUstekinumab q8wTotal
Female353267
Male192241
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ustekinumab q4wUstekinumab q8wTotal
Hispanic or Latino000
Not Hispanic or Latino5454108
Unknown or Not Reported000
08

Study locations

1 site
  • Ingrid Arijs
    Zaventem, 1930, Belgium
09

References and documents

Publications

  • Bossuyt P, Rahier JF, Baert F, Louis E, Macken E, Lobaton T, Busschaert J, Peeters H, Dewint P, Franchimont D, Willandt B, Claessens C, Vansteenkiste L, Dewit O, Ferrante M; Belgian IBD Research and Development (BIRD) group; Vermeire S. The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn's Disease: Results of the REScUE Study. Gastroenterology. 2026 Jul;171(1):99-109. doi: 10.1053/j.gastro.2026.01.042. Epub 2026 Feb 24. PubMed 41747777 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Sep 2024, 54 months.

Results were first posted in Apr 2026, 1 year 6 months after primary completion.

Of 88 phase 3 interventional studies under Crohn Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 69. This study's 54 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2020
First posted
Jan 28, 2020
StartActual
Mar 11, 2020
Primary completionActual
Sep 25, 2024
CompletionActual
Sep 25, 2024
Results first posted
Apr 13, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04245215
Lead sponsor
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
Mar 11, 2020
Primary completion
Sep 25, 2024
Completion
Sep 25, 2024
Results posted
Apr 13, 2026
Last update
Jul 1, 2026

Study contacts

Peter Bossuyt, MD
principal investigator · BIRD (Belgian IBD Research and Development) vzw

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ustekinumab

Start the discussion